Skip to Content

Phase 2 Data on Provectus's PV-10 to Be Presented at the HemOnc Today - Melanoma and Cutaneous Malignancies Conference on April 13, 2012

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Apr 10, 2012 - Provectus Pharmaceuticals, Inc. (OTCBB: PVCT,, a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 study of PV-10 for metastatic melanoma will be presented at the HemOnc Today – Melanoma and Cutaneous Malignancies Conference on April 13, 2012.

Professor Merrick Ross, M.D. of the MD Anderson Cancer Center in Houston, Texas, is scheduled to present at the HemOnc Today Conference in New York City. His presentation, entitled “Update on Intralesional Ablative Therapies” will begin at 1:55 p.m. EDT. Included in his discussion will be information about PV-10's Phase 2 studies, for which he is a Principal Investigator.

Dr. Craig Dees, PhD, CEO of Provectus said, “This is an exciting time for Provectus as we continue our development of PV-10, and make preparations for our pivotal Phase 3 study design. We expect Dr. Ross's presentation will give additional information about the Phase 2 trial of PV-10 for metastatic melanoma, and specifically, its systemic effect. This information, in concert with the recent immunology data presented at the Society of Surgical Oncology, we believe, will provide more insight to the medical community about the role that PV-10 can play in combating metastatic melanoma.”

About Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, For additional information about Provectus please visit the Company's website at or contact Porter, LeVay & Rose, Inc.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.


Contact: Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, 866-594-5999 #30
Porter, LeVay & Rose, Inc.
Marlon Nurse, DM, VP – Investor Relations
Bill Gordon, SVP – Media Relations



Posted: April 2012